MESO Q4 2021 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+188.4% YoY

Gross Profit

-$12M-604.8% margin

Operating Income

-$19M-966.7% margin

Net Income

-$22M-1105.2% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

+4.3%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$745M

Total Liabilities

$163M

Stockholders' Equity

$581M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$692,000	+188.4%
Gross Profit	-$12M	-$24M	+50.6%
Operating Income	-$19M	-$32M	+39.7%
Net Income	-$22M	-$33M	+32.4%